Joint association of remnant cholesterol and lipoprotein‐associated phospholipase A2 with composite adverse events: A 12‐year follow‐up study from Asymptomatic Polyvascular Abnormalities Community study

• DOI: 10.1111/dom.16286
• Publication Date: 2025-03-11T16:35:40Z
• Authors: Yuhe Liu; Liang Zhang; Yuehao Xu; Tianyun Zhou; Wenqian Wu; Kangnan Zhang; Rongdi Xu; Wangyang Chen; Weifang Xu; Yong Zhou; Xingdong Zheng; Baofu Chen
• Keywords: Lipoprotein-associated phospholipase A2

Abstract Aims To explore the association of remnant cholesterol (RC) and lipoprotein‐associated phospholipase A2 (Lp‐PLA2) with composite adverse events in a large‐scale prospective study. Methods All data were collected from Asymptomatic Polyvascular Abnormalities Community study between 2010 2022. Serum levels Lp‐PLA2 determined by enzyme‐linked immunosorbent assay. The participants categorized into four groups based on their RC levels: low‐RC/Lp‐PLA2−, high‐RC/Lp‐PLA2−, low‐RC/Lp‐PLA2+ high‐RC/Lp‐PLA2+. endpoint was combination first‐ever stroke, myocardial infarction or all‐cause mortality. Cox regression analyses performed to evaluate associations events. Results Of 1864 eligible participants, average age 60.6 years, 74.3% male. Over follow‐up 12 we identified 500 events, including 210 major cardiovascular 342 deaths. When compared group hazard ratios 95% confidence intervals high‐RC/Lp‐PLA2+ for infarction, event, death endpoints 1.37 (0.87–2.16), 0.72 (0.28–1.82), 1.29 (0.85–1.95), 1.61 (1.10–2.38) 1.43 (1.07–1.91), respectively. A significant interaction status has been found ( p <0.05). In addition, joint modified sex <60 versus ≥60 years interaction: 0.035 0.01, respectively). Conclusions Elevated associated an increased risk these significantly influenced age. Our highlights synergistic effect